Lisata Therapeutics Inc (LSTA)

[whirlybird]

Baxter P3 trial results will probably be positive

NBS could be a double winner.

On February 28, 2012 Baxter International Inc. (NYSE:BAX) announced it had “initiated a phase III pivotal clinical trial to evaluate the efficacy and safety of adult autologous (an individual's own) CD34+ stem cells to increase exercise capacity in patients with chronic myocardial ischemia (CMI). --- After stem cell mobilization, apheresis (collecting the cells from the body) and cell processing, participants received CD34+ stem cells or placebo in a single treatment via 10 intramyocardial injections into targeted areas of the heart tissue.” As many as 50 clinical sites enrolled 444 patients into this clinical trial. http://clinicaltrials.gov/ct2/show/NCT01508910

The Baxter stem cells were obtained from PCT, a subsidiary of NBS, in this RENEW study. Enrollment ended around December 2013 coincidentally about the same time that enrollment for the NBS PRESERVE P2 study ended. Some results are expected from both studies in about six months (around July 2014) from the end of enrollment around December 2013.

It is not just the announcement of PRESERVE P2 NBS results that could be a significant catalyst for NBS. If results of the RENEW study are positive milestones would probably be due to NBS and there would be future royalties and sales after the therapy is presumably approved.